Cargando…
GLI1 inhibitor GANT61 exhibits antitumor efficacy in T-cell lymphoma cells through down-regulation of p-STAT3 and SOCS3
T-cell lymphomas are lymphoid malignancies with aggressive clinical course and poor prognosis. Increasing evidences suggest that deregulation of signal transducer and activator of transcription-3 (STAT3) and suppressor of cytokine signaling 3 (SOCS3) is associated with the pathogenesis of T-cell lym...
Autores principales: | Geng, Lingyun, Lu, Kang, Li, Peipei, Li, Xinyu, Zhou, Xiangxiang, Li, Ying, Wang, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564718/ https://www.ncbi.nlm.nih.gov/pubmed/27275540 http://dx.doi.org/10.18632/oncotarget.9792 |
Ejemplares similares
-
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
por: Li, Jianlong, et al.
Publicado: (2016) -
Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding
por: Agyeman, Akwasi, et al.
Publicado: (2014) -
Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells
por: Wang, Jing, et al.
Publicado: (2014) -
Targeting GLI by GANT61 involves mechanisms dependent on inhibition of both transcription and DNA licensing
por: Zhang, Ruowen, et al.
Publicado: (2016) -
In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors
por: Benvenuto, Monica, et al.
Publicado: (2016)